Modafinil history: from Lafon's lab to Provigil and generics

Key points

• Modafinil came out of work at the French company L. Lafon: adrafinil was identified in 1974, Michel Jouvet gave it to narcolepsy patients in 1977-78, and modafinil, its active metabolite, from 1983 [1].
• The first French marketing authorisation is dated 24 June 1992 in the French public drug database; the French register also holds a commercialisation declaration dated 19 October 1994. The “1992 vs 1994” disagreement is registration vs launch [1][2].
• FDA approved Provigil on 24 December 1998; DEA placed modafinil in Schedule IV with effect from 27 January 1999 [3][5].
• Cephalon, then Teva, owned the brand. Generic modafinil followed a patent fight that ended in an FTC case and a 2015 settlement [8][9].
• The shift to “smart drug” use is documented mainly by reviews of non-medical use, not by a dated event [13].

Where did modafinil come from?

The most cited history is a 2018 review by Michel Billiard and Roger Broughton in Sleep Medicine. We could read its abstract but not the full text, so everything below attributed to it comes from the abstract only [1].

According to the abstract, Lafon identified adrafinil in 1974; it raised motor activity in mice without peripheral sympathomimetic effects. Jouvet prescribed adrafinil to narcolepsy patients in 1977-78 with inconsistent results. Modafinil was identified as its active metabolite, and in 1983 Jouvet and Bastuji prescribed it to patients with narcolepsy and idiopathic hypersomnia, reducing sleepiness and sleep attacks in most. Lafon “initially had no interest” in marketing it, but at Jouvet’s urging ran studies in healthy volunteers, patients and animals. The abstract then links the results to use by the French army in the 1991 Gulf War and to French registration in 1992 [1].

That is the documented core. Details we could not verify from a source we opened: the exact synthesis date of modafinil itself, who at Lafon chose to pursue it, and how widely the army used it. Popular accounts add colourful detail on all three; treat it as legend until a primary source is cited.

When was modafinil first registered in France: 1992 or 1994?

Both dates exist, and they describe different events.

• 1992. The abstract of Billiard and Broughton places “official registration” in France in 1992 [1]. The French public drug database (base de données publique des médicaments) lists a marketing authorisation (AMM) date of 24 June 1992 for Modiodal 100 mg tablets [2].
• 1994. The same database entry shows a commercialisation declaration of 19 October 1994 for the 30-tablet pack [2].

What we can support: authorisation in 1992, a recorded market declaration in 1994. What we could not support: that authorisation happened in 1994. Two cautions. The database record is the current entry, held today by a different company (NEURAXPHARM, Spain), so it shows the dates attached to the product, not who held them in 1992 [2]. And the 1994 declaration is for one pack size; earlier packs or a different launch date may exist that we did not see. The EMA’s French-language referral annex also lists holders, but we could not read the file, so we do not rely on it.

How did the US approval and scheduling unfold?

Cephalon’s US rights came from Lafon. A 2002 trade report says Lafon first licensed Cephalon the rights to develop and sell Provigil in the US in 1993 [6].

In its 14 April 1998 notice the DEA proposed to place modafinil in Schedule IV “if and when” the new drug application was approved, and noted FDA had issued an approvable letter on 29 December 1997 [4]. Drugs@FDA lists NDA 020717 (Provigil) as approved on 24 December 1998, a new molecular entity with orphan status [3]. The DEA’s final rule, effective 27 January 1999, states that FDA told it on 30 December 1998 about the 24 December approval. It found modafinil has “a low potential for abuse relative to the drugs or other substances in Schedule III” and that abuse may lead to limited physical and psychological dependence. Cephalon filed the only comment, which did not object to Schedule IV [5].

Note a common slip: Cephalon announced the approval on 28 December 1998, but the approval date of record is 24 December [3][5]. The original US indication was excessive sleepiness in narcolepsy. The current label also covers sleep apnea and shift work disorder, see the complete modafinil guide.

Who owned modafinil: Lafon, Cephalon, Teva?

• Cephalon and Lafon. On 28 December 2001 Cephalon announced it had completed the acquisition of Group Lafon and “now controls worldwide rights” to Provigil, its “flagship product”, plus Lafon’s Mitry-Mory plant, where the active ingredient is made [7]. A trade report put the price at US$450 million in cash [6]; the release we read gives no price.
• Teva and Cephalon. Teva announced completion of its acquisition of Cephalon on 14 October 2011, with $81.50 in cash per Cephalon share [10]. The release does not mention Provigil. An FTC release says Teva acquired Cephalon in 2012; we follow the SEC-filed release for the date [10][12].

Drugs@FDA still lists Provigil under a different sponsor name today (Nuvo Pharms) [3]; we did not trace the later transfers.

What is armodafinil, and when was it approved?

Armodafinil is the R-enantiomer of modafinil, sold as Nuvigil. Drugs@FDA lists NDA 021875 as approved on 15 June 2007 [14]. A Cephalon release dated 18 June 2007, as reproduced by BioSpace, described Nuvigil as the single-isomer form with a longer duration, with a US patent expiring in 2023 [15]. The comparison is in modafinil vs armodafinil.

What happened to patents and generics?

According to the FTC, which sued Cephalon on 13 February 2008, the “only remaining patent” on Provigil was a narrow formulation patent about particle size. Cephalon agreed with four generic makers (Teva, Ranbaxy, Mylan, Barr) to pay “in excess of $200 million” in total, and they agreed not to sell generics until April 2012. The FTC cited US Provigil sales over $800 million in 2007, above 40% of Cephalon’s sales [8]. These are the FTC’s allegations in the 2008 complaint.

The FTC case ended on 28 May 2015: Teva agreed to make $1.2 billion available to purchasers, with an order restricting similar deals [9]. Private litigation continued; a 2016 Third Circuit ruling in In re Modafinil Antitrust Litigation (No. 15-3475) concerned class certification, but we could only see a summary and do not rely on its content. We did not check the Orange Book for patent listings or ANDA approvals; entry dates beyond the FTC’s April 2012 agreed date are unverified.

When did Europe restrict modafinil?

After a review, the EMA recommended in 2010 and the Commission decided in January 2011 that modafinil should be restricted to narcolepsy; see the complete guide for the dates and sources [16].

How did off-label and “smart drug” use develop?

We found no regulator record of a start date. What reviews document is the result. A 2022 review in Drugs (Schifano and colleagues) says healthy users take cognitive enhancers mostly to improve memory, attention and executive function and generally perceive them as effective, while efficacy in healthy people “is uncertain and any reported improvement temporary” [13]. Prevalence estimates in the literature are wide, and we could not verify a single reliable figure.

We could not open the Justice Department’s 2008 Cephalon settlement documents and so say nothing about off-label promotion by the company. Meta-analyses of healthy-adult trials are summarised in the complete guide.

Legal and regulatory status (checked 8 Nov 2026)

US: prescription-only, Schedule IV, approved for excessive sleepiness in narcolepsy, sleep apnea and shift work disorder [3][5]. EU: narrowed to narcolepsy in 2011 [16]. France: the public database lists the current product for adults with excessive sleepiness associated with narcolepsy [2]. UK and Germany: not rechecked here; see the complete guide. This is a prescription medicine, so “research use only” does not apply.

Risks and unknowns

This is a history article and not a safety review. Documented risks (serious skin reactions, psychiatric events, reduced hormonal contraceptive effect, pregnancy questions) are in the complete guide. Unknowns specific to this history: the full text of the key historical review, the French authorisation text from 1992, and the Orange Book record were not available to us.

Frequently asked questions

Who discovered modafinil?

It was developed at the French company L. Lafon, where adrafinil was identified in 1974; Michel Jouvet’s clinical work on narcolepsy led to modafinil in 1983 [1]. Attribution to a single inventor is not supported by what we could read.

When was modafinil first approved?

France authorised it on 24 June 1992 per the French public database [2]. The FDA approved Provigil on 24 December 1998 [3].

Why do some sources say 1994?

The French register records a commercialisation declaration on 19 October 1994 [2]. That is a launch record, not the authorisation date.

When did generic modafinil appear in the US?

The FTC said four generic makers agreed to wait until April 2012 [8]. We did not verify the actual first generic approval or launch date.

Sources

1. Billiard M, Broughton R, “Modafinil: its discovery, the early European and North American experience…”, Sleep Med 2018;49:69-72 (abstract read through Europe PMC; PubMed blocked). https://pubmed.ncbi.nlm.nih.gov/30174215/
2. ANSM / French health ministry, “MODIODAL 100 mg, comprimé” (public drug database, updated 29 June 2026). https://base-donnees-publique.medicaments.gouv.fr/medicament/66805883/extrait
3. FDA, “Drugs@FDA: NDA 020717 Provigil, overview” (accessed 2026-11-08). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020717
4. DEA, “Schedules of Controlled Substances: Proposed Placement of Modafinil Into Schedule IV”, Federal Register 63 (14 Apr 1998). https://www.govinfo.gov/content/pkg/FR-1998-04-14/html/98-9824.htm
5. DEA, “Schedules of Controlled Substances: Placement of Modafinil Into Schedule IV”, Federal Register 64 (27 Jan 1999). https://www.govinfo.gov/content/pkg/FR-1999-01-27/html/99-1791.htm
6. Manufacturing Chemist, “Cephalon to acquire French pharma group” (19 Jan 2002). https://manufacturingchemist.com/cephalon-to-acquire-french-pharma-group--31032
7. Cephalon, press release on completion of the Group Lafon acquisition, SEC Form 8-K exhibit 99.1 (28 Dec 2001). https://www.sec.gov/Archives/edgar/data/0000873364/000091205702000878/a2067212zex-99_1.txt
8. FTC, “FTC Sues Cephalon, Inc. for Unlawfully Blocking Sale of Lower-Cost Generic Versions of Branded Drug Until 2012” (13 Feb 2008). https://www.ftc.gov/news-events/news/press-releases/2008/02/ftc-sues-cephalon-inc-unlawfully-blocking-sale-lower-cost-generic-versions-branded-drug-until-2012
9. FTC, “FTC Settlement of Cephalon Pay for Delay Case Ensures $1.2 Billion in Ill-Gotten Gains Relinquished…” (28 May 2015). https://www.ftc.gov/news-events/news/press-releases/2015/05/ftc-settlement-cephalon-pay-delay-case-ensures-12-billion-ill-gotten-gains-relinquished-refunds-will
10. Teva, press release “Teva Completes Acquisition of Cephalon”, SEC Form 8-K exhibit 99.1 (14 Oct 2011). https://www.sec.gov/Archives/edgar/data/0000873364/000110465911056145/a11-28026_1ex99d1.htm
11. In re Modafinil Antitrust Litig., No. 15-3475 (3d Cir. 13 Sep 2016): page blocked (HTTP 403); search summary only, not relied on. https://law.justia.com/cases/federal/appellate-courts/ca3/15-3475/15-3475-2016-09-13.html
12. See [9] (statement that Teva acquired Cephalon in 2012, in conflict with [10]).
13. Schifano F et al., “Benefits and Harms of ‘Smart Drugs’ (Nootropics) in Healthy Individuals”, Drugs 2022;82(6):633-647 (abstract read through Europe PMC). https://pubmed.ncbi.nlm.nih.gov/35366192/
14. FDA, “Drugs@FDA: NDA 021875 Nuvigil, overview” (accessed 2026-11-08). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021875
15. BioSpace, “Cephalon, Inc. Wins U.S. Approval for Nuvigil Sleep Drug” (18 Jun 2007). https://www.biospace.com/cephalon-inc-wins-u-s-approval-for-nuvigil-sleep-drug
16. EMA, “Modafinil - referral” (CHMP opinion 18 Nov 2010, Commission decision 27 Jan 2011), as cited in our complete guide; not reopened for this article. https://www.ema.europa.eu/en/medicines/human/referrals/modafinil

This article is information, not medical advice.